Current landscape of palliative radiotherapy for non-small-cell lung cancer | Zendy

R. Jumeau | Zendy; Florent Vilotte | Zendy; AndréDante Durham | Zendy; E.M. Ozsahin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Current landscape of palliative radiotherapy for non-small-cell lung cancer

Author(s) -

R. Jumeau,

Florent Vilotte,

AndréDante Durham,

E.M. Ozsahin

Publication year - 2019

Publication title -

translational lung cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.474

H-Index - 41

eISSN - 2226-4477

pISSN - 2218-6751

DOI - 10.21037/tlcr.2019.08.10

Subject(s) - medicine , lung cancer , sabr volatility model , radiation therapy , palliative care , immunotherapy , concomitant , oncology , stage (stratigraphy) , ablative case , radiosurgery , brachytherapy , chemotherapy , cancer , radiology , volatility (finance) , paleontology , stochastic volatility , nursing , financial economics , economics , biology

Radiotherapy (RT) is a cornerstone in the management of advanced stage III and stage IV non-small-cell lung cancer (NSCLC) patients. Despite international guidelines, clinical practice remains heterogeneous. Additionally, the advent of stereotactic ablative RT (SABR) and new systemic treatments such as immunotherapy have shaken up dogmas in the approach of these patients. This review will focus on palliative thoracic RT for NSCLC but will also discuss the role of stereotactic radiotherapy, endobronchial brachytherapy (EBB), the interest of concomitant treatments (chemotherapy and immunotherapy), and the role of RT in lung cancer emergencies with palliative intent.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research